{"answer":{"query":"tradjenta","resolved_as":"name","packages":4,"applications":["NDA201280"],"identity":{"application_numbers":["NDA201280"],"marketing_categories":["NDA"],"labelers":[{"text":"BOEHRINGER INGELHEIM PHARMACEUTICALS","untrusted":true}],"dosage_forms":[{"text":"TABLET, FILM COATED","untrusted":true}],"marketing_start":{"earliest":"2011-05-09","latest":"2011-05-09","packages_with_a_start_date":3}},"price":{"median_negotiated_over_nadac":null,"packages_compared":0,"packages_listed":4,"negotiated_price_ends":null,"rows":[{"ndc":"00597014010","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00597014030","name":{"text":"Tradjenta Tablets, 5mg","untrusted":true},"class":"B","nadac_per_unit":16.7954,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00597014061","name":{"text":"Tradjenta Tablets, 5mg 100s","untrusted":true},"class":"B","nadac_per_unit":16.7954,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00597014090","name":{"text":"Tradjenta Tablets, 5mg","untrusted":true},"class":"B","nadac_per_unit":16.7954,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null}],"negotiated_scheduled":{"thirty_day":78,"effective":"2027-01-01"}},"generic_entry":[{"application":"NDA201280","date":"2037-12-08","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"12364700*PED","productNo":"001"},"latest_patent_expiry":"2037-12-08","latest_exclusivity_expiry":"2026-12-20","dated_barriers":20,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":10,"exclusivities_listed":2,"fact_id":"9b9b68241e2e8ad540ea72e4"}],"label_history":{"events_total":18,"non_cmc_events":16,"counts_by_class":{"EFFICACY":7,"LABELING":9},"cmc_events":2,"recent_non_cmc_events":[{"application":"NDA201280","submission_no":27,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2023-06-20","documents":[{"type":"Letter","date":"2023-06-21","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/201280Orig1s027ltr.pdf","untrusted":true}},{"type":"Label","date":"2023-06-22","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201280s027lbl.pdf","untrusted":true}}],"fact_id":"4886ae13201a616ef35e07ac"},{"application":"NDA201280","submission_no":25,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2022-04-15","documents":[{"type":"Letter","date":"2022-04-18","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/201280Orig1s025; 201281Orig1s031ltr.pdf","untrusted":true}},{"type":"Label","date":"2022-04-18","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201280s025lbl.pdf","untrusted":true}}],"fact_id":"0a749e5c305ccac9a8cdbec0"},{"application":"NDA201280","submission_no":20,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2020-03-30","documents":[{"type":"Letter","date":"2020-03-31","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/201280Orig1s020, 201281Orig1s024, 206073Orig1s021, 208026Orig1s012ltr.pdf","untrusted":true}},{"type":"Label","date":"2020-03-31","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/201280s020lbl.pdf","untrusted":true}}],"fact_id":"4e896df773ab5bd053c114d6"},{"application":"NDA201280","submission_no":18,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2019-07-03","documents":[{"type":"Letter","date":"2019-07-05","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/201280Orig1s018, 201281Orig1s022, 206073Orig1s017, 208026Orig1s008ltr.pdf","untrusted":true}},{"type":"Label","date":"2019-09-10","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201280s018lbl.pdf","untrusted":true}}],"fact_id":"ec87eb47264ee59ada286ecd"},{"application":"NDA201280","submission_no":21,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2019-07-01","documents":[{"type":"Letter","date":"2019-07-02","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/201280Orig1s021, 201281Orig1s025, 206073Orig1s022, 208026Orig1s013ltr.pdf","untrusted":true}},{"type":"Label","date":"2019-07-08","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201280s021lbl.pdf","untrusted":true}}],"fact_id":"366cb30bd8a42f55c9ff4fdd"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":1,"te_code_counts":{"AB":1},"marketing_status_counts":{"Prescription":1},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA201280","product_no":"001","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"TRADJENTA","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"5MG","untrusted":true}}]},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"LINAGLIPTIN","untrusted":true},"recruiting_interventional_count":6,"not_yet_recruiting_count":6,"by_phase":{"PHASE4":4,"PHASE3":1,"NA":1},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT06862739","title":{"text":"Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"Nabiqasim Industries (Pvt) Ltd","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-04-17","start_date":"2025-10-30","link":{"text":"https://clinicaltrials.gov/study/NCT06862739","untrusted":true}},{"nct_id":"NCT07442006","title":{"text":"Glycemic Variability of Combination Therapies in T2DM","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"JW Pharmaceutical","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-03-02","start_date":"2025-10-29","link":{"text":"https://clinicaltrials.gov/study/NCT07442006","untrusted":true}},{"nct_id":"NCT04670666","title":{"text":"Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"EMS","untrusted":true},"status":"RECRUITING","last_update_posted":"2025-12-08","start_date":"2024-11-18","link":{"text":"https://clinicaltrials.gov/study/NCT04670666","untrusted":true}},{"nct_id":"NCT07019012","title":{"text":"Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"Huazhong University of Science and Technology","untrusted":true},"status":"RECRUITING","last_update_posted":"2025-06-13","start_date":"2025-07-30","link":{"text":"https://clinicaltrials.gov/study/NCT07019012","untrusted":true}},{"nct_id":"NCT06095492","title":{"text":"Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus","untrusted":true},"phase":["NA"],"sponsor":{"text":"Medanta, The Medicity, India","untrusted":true},"status":"RECRUITING","last_update_posted":"2024-12-05","start_date":"2023-10-30","link":{"text":"https://clinicaltrials.gov/study/NCT06095492","untrusted":true}}],"fact_id":"602880f8078a0b44009e6d5f"}]},"spending":{"reported_under":{"generic":{"text":"Linagliptin","untrusted":true},"brand":{"text":"Tradjenta","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":1288663292.9,"claims":1831827,"beneficiaries":330487,"average_spending_per_claim_usd":703.48525974,"fact_id":"a2b839cf7b35b11ff37cbfb6"},{"year":2021,"gross_spending_usd":1318071297.6,"claims":1693113,"beneficiaries":318685,"average_spending_per_claim_usd":778.48985719,"fact_id":"c768906ca15f99ffa9ace1bc"},{"year":2022,"gross_spending_usd":1326573078.6,"claims":1615560,"beneficiaries":305131,"average_spending_per_claim_usd":821.12275535,"fact_id":"0cbb03edc032d0bc7c4161b7"},{"year":2023,"gross_spending_usd":1293567778.3,"claims":1496546,"beneficiaries":286808,"average_spending_per_claim_usd":864.36887226,"fact_id":"f1125e9d3e47c0f4ce2dfb9e"},{"year":2024,"gross_spending_usd":1127598446.4,"claims":1446832,"beneficiaries":274523,"average_spending_per_claim_usd":779.35686134,"fact_id":"1412acf713633a8569d0a6f0"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"medicaid_state_utilization":{"year":2025,"states_with_data":1,"all_states_medicaid_reimbursed_usd":4185.45,"all_states_medicaid_paid_prescriptions":77,"top_states":[{"state":"KY","medicaid_paid_prescriptions":77,"medicaid_reimbursed_usd":4185.45,"total_reimbursed_usd":4185.45,"packages":1,"covers":"fee_for_service_only","fact_id":"1f4b6f350ba05b2e3131c41d"}],"unlabelled_state_code_xx":null,"built_from_facts":1,"facts_fee_for_service_only":1,"older_year_facts_not_used":87,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"6256bc17ef290d658f4bd8e6","field":"ndc.listing","entity":"ndc:00597014030"},{"fact_id":"b552bae180f3dd61857e813d","field":"ndc.listing","entity":"ndc:00597014061"},{"fact_id":"59bdea3f96b8371c3c0efffc","field":"ndc.listing","entity":"ndc:00597014090"},{"fact_id":"9b9b68241e2e8ad540ea72e4","field":"drug.generic_entry_earliest","entity":"application:NDA201280"},{"fact_id":"66ee05f279edf2c2e0fba095","field":"drug.patent","entity":"application:NDA201280"},{"fact_id":"c42b4a8c1d7a88c10a6060a9","field":"drug.exclusivity","entity":"application:NDA201280"},{"fact_id":"4886ae13201a616ef35e07ac","field":"drug.label_event","entity":"application:NDA201280"},{"fact_id":"0a749e5c305ccac9a8cdbec0","field":"drug.label_event","entity":"application:NDA201280"},{"fact_id":"4e896df773ab5bd053c114d6","field":"drug.label_event","entity":"application:NDA201280"},{"fact_id":"ec87eb47264ee59ada286ecd","field":"drug.label_event","entity":"application:NDA201280"},{"fact_id":"366cb30bd8a42f55c9ff4fdd","field":"drug.label_event","entity":"application:NDA201280"},{"fact_id":"6e7ea5c636c27d364863e913","field":"drug.te_code","entity":"application:NDA201280"},{"fact_id":"488693d6b600a039edac4891","field":"drug.marketing_status","entity":"application:NDA201280"},{"fact_id":"602880f8078a0b44009e6d5f","field":"drug.trial_access","entity":"drug:linagliptin"},{"fact_id":"a2b839cf7b35b11ff37cbfb6","field":"drug.partd_spending","entity":"drug:linagliptin|tradjenta"},{"fact_id":"c768906ca15f99ffa9ace1bc","field":"drug.partd_spending","entity":"drug:linagliptin|tradjenta"},{"fact_id":"0cbb03edc032d0bc7c4161b7","field":"drug.partd_spending","entity":"drug:linagliptin|tradjenta"},{"fact_id":"f1125e9d3e47c0f4ce2dfb9e","field":"drug.partd_spending","entity":"drug:linagliptin|tradjenta"},{"fact_id":"1412acf713633a8569d0a6f0","field":"drug.partd_spending","entity":"drug:linagliptin|tradjenta"},{"fact_id":"1f4b6f350ba05b2e3131c41d","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597014061:KY"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price.ratio","reason":"no package has both a brand-class NADAC price and a negotiated price in force"},{"code":"NO_DATA","field":"recalls","reason":"no FDA enforcement report naming a package of these applications is recorded"},{"code":"NO_DATA","field":"supply","reason":"no FDA shortage row and no termination date for these packages"},{"code":"NO_DATA","field":"assistance_and_offers","reason":"no assistance program lists this drug and no manufacturer offer naming it is recorded; that does not mean none exists"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"rems","reason":"no REMS@FDA program is tied to these applications in the edition (most drugs have none)"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"orphan_designation","reason":"no FDA orphan designation for this drug's ingredient is in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}